Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07272629 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.

A Phase 1 study of Healthy Volunteers and Cardiac Repolarization, sponsored by Sanofi.

Recruiting
Registry status
Phase 1
Development phase
44
Enrollment target
2
Study locations

NCT07272629 is a Phase 1 study of Healthy Volunteers and Cardiac Repolarization that is actively recruiting participants, run by Sanofi. The registered enrollment target is 44 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07272629, a Phase 1 study of Healthy Volunteers and Cardiac Repolarization, is actively recruiting participants, sponsored by Sanofi.

RECRUITING
Registry status
Phase 1
Development phase
44 participants
Enrollment target
2
Study locations

Study Summary

This is a Phase 1, multicenter, randomized, double-blind, double-dummy, single dose, placebo- and positive-controlled, 4-sequence, 4-treatment, 4-period crossover study.

Interventions

  • DRUG Placebo
  • DRUG Balinatunfib
  • DRUG Moxifloxacin

Study Locations (2)

Texas

  • FORTREA CLINICAL RESEARCH UNIT INC- Site Number : 8400002 - Dallas

Wisconsin

  • FORTREA CLINICAL RESEARCH UNIT INC- Site Number : 8400001 - Madison

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2025-12-04
Est. Completion 2026-04-27
Phase Phase 1

Sponsor

Sanofi

713 total trials

What the Registry Record Tells You About NCT07272629

The ClinicalTrials.gov registry entry for NCT07272629 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (91% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Healthy Volunteers appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT07272629 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT07272629 about?

NCT07272629 is a clinical study titled "A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.". This is a Phase 1, multicenter, randomized, double-blind, double-dummy, single dose, placebo- and positive-controlled, 4-sequence, 4-treatment, 4-period crossover study.

What is the current status of trial NCT07272629?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2025-12-04. Estimated completion is 2026-04-27.

What conditions does trial NCT07272629 study?

This clinical trial studies the following conditions: Healthy Volunteers, Cardiac Repolarization.

What interventions are being tested in trial NCT07272629?

The interventions under investigation include: Placebo (DRUG), Balinatunfib (DRUG), Moxifloxacin (DRUG).

Who is sponsoring clinical trial NCT07272629?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07272629 being conducted?

This trial has 2 study locations across Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.